Photo Release -- Samaritan Recognized for HIV Innovation

Frost & Sullivan's 'North American Technology Innovation Award' Goes to Samaritan's SP-01A, a Unique HIV Entry Inhibitor LAS VEGAS, Nov. 16, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. and Samaritan PharmaPlaz Ireland, Inc. (AMEX:LIV) a developer of innovative drugs, announced today it has been selected by the prestigious Frost & Sullivan Best Practices Group to receive the 2006 North American Technology Innovation Award, for its HIV Entry Inhibitor Drug Candidate SP-01A targeting HIV drug resistance. A photo accompanying this release is available at "This award is a testament to the dedication of our scientists at Samaritan Labs, Georgetown University, our in-house drug development team, PharmaPlaz, Ireland, Samaritan's collaborative manufacturing partner and last but not least, our administrative team," stated Dr. Janet Greeson, CEO of Samaritan. "I'd like to thank everyone for the vital roles they've played in making it possible for Samaritan to be honored with this award." According to Frost & Sullivan: "The Frost & Sullivan 2006 Technology Innovation Award in the field of HIV drug development goes to Samaritan Pharmaceuticals, Inc. in recognition of the company's effort in developing the antiviral therapy based drug, SP01A. Notably, this therapeutic treatment offers respite as a drug that does not develop resistance along with ensuring safety and tolerance levels while delivering the required action." Excerpts from Award: -- "This drug would come across as one that eliminates side effects and noncompliance issues, and, hence, has a cutting edge over the other antiretroviral therapies." -- "This seems a better mode of prevention as it stops the HIV virus from invading healthy cells rather than attacking the virus, when it has already established itself in the cell." "In summary, the Frost & Sullivan 2006 Technology Innovation Award recognizes Samaritan Pharmaceuticals, Inc. for its development of a novel-therapy solution targeting HIV. This solution incorporates a unique entry-level inhibitor that does not confer resistance or cross-resistance while ensuring patient safety and exhibiting high potent inhibition toward HIV." To read full Frost & Sullivan award commentary, go to About Frost & Sullivan: Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit Samaritan Pharmaceuticals: "We Save Lives." Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at Please register on Website so we can notify you of upcoming conference calls, news and events. The Samaritan Pharmaceuticals Inc. logo is available at Disclaimer The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K/A filed November 2, 2006. The company undertakes no duty to update forward-looking statements. The photo is also available at NewsCom, (, and via AP PhotoExpress. CONTACT: Samaritan Pharmaceuticals, Inc. Richard Brown (702) 735-7001